Studies on the tumour responsiveness to chemo- or immunotherapies revealed that butyrate could also boost the efficacy of the chemotherapeutic drug oxaliplatin by modulating CD8+ T cell function and promoting the IL-12 signalling pathway in the tumour microenvironment [34]. This evidence concerns the gene CD8A and neoplasm.